Nirsevimab

Nirsevimab Uses, Dosage, Side Effects, Food Interaction and all others data.

Nirsevimab is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI) in High-risk Children).

Trade Name Nirsevimab
Generic Nirsevimab
Nirsevimab Other Names Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03, Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897 .gamma.1-chain), disulfide with monoclonal med18897 .kappa.-chain, dimer, Nirsevimab
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Nirsevimab
Nirsevimab

Innovators Monograph

You find simplified version here Nirsevimab


*** Taking medicines without doctor's advice can cause long-term problems.
Share